<p>Larimar Therapeutics（納斯達克代碼：LRMR - 獲取免費報告）預計將在 2025 年 3 月 30 日星期一市場開盤前發佈其 2025 年第四季度財報。分析師預計該公司將在本季度宣佈每股收益為（$0.41）。投資者可以在公司即將發佈的 2025 年第四季度財報頁面上找到電話會議的詳細信息，最新的電話會議安排在 2026 年 3 月 25 日星期三東部時間下午 12:30。</p>
<p>獲取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
<ul>
<li>按表現排名的最佳股票選擇人工智能</li>
</ul>
<p>Larimar Therapeutics（納斯達克代碼：LRMR - 獲取免費報告）最近於 3 月 19 日星期四發佈了季度財報。該公司報告本季度每股收益為（$0.73），低於市場共識預期的（$0.43），差距為（$0.30）。分析師平均預計 Larimar Therapeutics 在當前財年將發佈每股收益為$-1，下一財年為$-2。</p>
<h2>Larimar Therapeutics 股價上漲 0.4%</h2>
<p>Larimar Therapeutics 的股票在星期一以$4.49 開盤。該公司的市值為 4.6642 億美元，市盈率為-2.03，貝塔值為 0.90。該公司的 50 日移動平均價格為$3.95，200 日移動平均價格為$3.92。Larimar Therapeutics 的 1 年最低價為$1.61，1 年最高價為$6.42。</p>
<h2>內部人士活動</h2>
<p>在其他新聞中，董事 James E. Flynn 於 2 月 27 日星期五購買了 5,000,000 股該股票，交易的平均價格為每股$5.00，總交易額為$25,000,000.00。完成收購後，該董事直接持有公司 10,622,957 股，估值約為$53,114,785。這筆交易代表其持股比例增加了 88.92%。該購買在向 SEC 的法律文件中披露，可以通過此超鏈接訪問。目前，4.50% 的股票由內部人士持有。</p>
<h2>機構投資者對 Larimar Therapeutics 的看法</h2>
<p>一些機構投資者最近增加或減少了對該公司的持股。法國巴黎銀行金融市場在第三季度將其在 Larimar Therapeutics 的持股增加了 75.8%。法國巴黎銀行金融市場現在擁有 10,146 股該公司的股票，價值$33,000，在上個季度又購買了 4,376 股。美國世紀公司在第二季度將其在 Larimar Therapeutics 的持股增加了 7.8%。美國世紀公司現在擁有 69,285 股該公司的股票，價值$200,000，在上個季度又收購了 5,001 股。Price T Rowe Associates Inc. MD 在第四季度將其在 Larimar Therapeutics 的持股增加了 26.3%。Price T Rowe Associates Inc. MD 現在擁有 29,008 股該公司的股票，價值$111,000，在上個季度又收購了 6,038 股。巴克萊銀行在第四季度將其在 Larimar Therapeutics 的持股增加了 10.7%。巴克萊銀行現在擁有 78,470 股該公司的股票，價值$299,000，在上個季度又收購了 7,577 股。最後，Rhumbline Advisers 在第一季度將其在 Larimar Therapeutics 的持股增加了 15.7%。Rhumbline Advisers 現在擁有 65,018 股該公司的股票，價值$140,000，在上個季度又收購了 8,818 股。91.92% 的股票由機構投資者持有。</p>
<h2>分析師升級和降級</h2>
<p>LRMR 成為多份分析師報告的主題。Wedbush 在週五的報告中將 Larimar Therapeutics 的目標價格從$12.00 上調至$13.00，並給予該股票 “跑贏大盤” 的評級。花旗集團在 2 月 25 日星期三的研究報告中將 Larimar Therapeutics 的目標價格從$12.00 上調至$14.00，並給予該公司 “買入” 評級。Leerink Partners 在 1 月 5 日星期一的報告中將 Larimar Therapeutics 的評級提升至 “強烈買入”。Weiss Ratings 在 1 月 22 日星期四的研究報告中重新發布了對 Larimar Therapeutics 的 “賣出（d-）” 評級。最後，Lifesci Capital 在 2 月 24 日星期二的報告中將 Larimar Therapeutics 的評級提升至 “強烈買入”。兩位股票研究分析師對該股票給予了 “強烈買入” 評級，七位給予了 “買入” 評級，一位給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “買入”，共識目標價格為$16.43。</p>
<p><strong>閲讀我們關於 LRMR 的最新股票報告</strong></p>
<h2>關於 Larimar Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Larimar Therapeutics, Inc 是一家臨牀階段的生物技術公司，專注於利用其新型細胞穿透肽技術平台開發罕見疾病的治療方案。其主要產品候選藥物 CTI-1601 目前正在進行針對弗里德里希共濟失調的第二階段 OLE 臨牀試驗，這是一種罕見的、進行性且致命的遺傳疾病。Larimar Therapeutics, Inc 總部位於賓夕法尼亞州巴拉金伍德。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更喜歡的五隻股票，勝過 Larimar Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxSTVI?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUxSTVI"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Larimar Therapeutics 嗎？</h2>
<p>在你考慮 Larimar Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Larimar Therapeutics 並不在名單上。</p>
<p>雖然 Larimar Therapeutics 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看五隻股票</p>

LRMR

<p>Larimar Therapeutics（納斯達克代碼：LRMR）將於 3 月 30 日公佈 2025 年第四季度財報，分析師預測每股虧損 0.41 美元。該公司最近報告了上一季度每股虧損 0.73 美元，未能達到預期。當前股票交易價格為 4.49 美元，市值為 4.6642 億美元。內部人士 James E. Flynn 購買了 500 萬股，顯著增加了他的持股比例。分析師的評級意見不一，普遍為 “買入”，目標價格為 16.43 美元</p>

<p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 12:30 PM ET.</p>
<div class="lb-trans"><p>Larimar Therapeutics（納斯達克代碼：LRMR - 獲取免費報告）預計將在 2025 年 3 月 30 日星期一市場開盤前發佈其 2025 年第四季度財報。分析師預計該公司將在本季度宣佈每股收益為（$0.41）。投資者可以在公司即將發佈的 2025 年第四季度財報頁面上找到電話會議的詳細信息，最新的電話會議安排在 2026 年 3 月 25 日星期三東部時間下午 12:30。</p>
</div><p>Get <strong>Larimar Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Larimar Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>按表現排名的最佳股票選擇人工智能</li>
</ul>
</div><p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.30). On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Larimar Therapeutics（納斯達克代碼：LRMR - 獲取免費報告）最近於 3 月 19 日星期四發佈了季度財報。該公司報告本季度每股收益為（$0.73），低於市場共識預期的（$0.43），差距為（$0.30）。分析師平均預計 Larimar Therapeutics 在當前財年將發佈每股收益為$-1，下一財年為$-2。</p>
</div><h2>Larimar Therapeutics Trading Up 0.4%</h2>
<div class="lb-trans"><h2>Larimar Therapeutics 股價上漲 0.4%</h2>
</div><p>Larimar Therapeutics stock opened at $4.49 on Monday. The firm has a market capitalization of $466.42 million, a price-to-earnings ratio of -2.03 and a beta of 0.90. The firm's fifty day moving average price is $3.95 and its two-hundred day moving average price is $3.92. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $6.42.</p>
<div class="lb-trans"><p>Larimar Therapeutics 的股票在星期一以$4.49 開盤。該公司的市值為 4.6642 億美元，市盈率為-2.03，貝塔值為 0.90。該公司的 50 日移動平均價格為$3.95，200 日移動平均價格為$3.92。Larimar Therapeutics 的 1 年最低價為$1.61，1 年最高價為$6.42。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部人士活動</h2>
</div><p>In other news, Director James E. Flynn bought 5,000,000 shares of the stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $5.00 per share, for a total transaction of $25,000,000.00. Following the completion of the acquisition, the director directly owned 10,622,957 shares in the company, valued at approximately $53,114,785. This trade represents a 88.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.50% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 James E. Flynn 於 2 月 27 日星期五購買了 5,000,000 股該股票，交易的平均價格為每股$5.00，總交易額為$25,000,000.00。完成收購後，該董事直接持有公司 10,622,957 股，估值約為$53,114,785。這筆交易代表其持股比例增加了 88.92%。該購買在向 SEC 的法律文件中披露，可以通過此超鏈接訪問。目前，4.50% 的股票由內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Larimar Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Larimar Therapeutics 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in Larimar Therapeutics by 75.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company's stock valued at $33,000 after buying an additional 4,376 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Larimar Therapeutics by 7.8% in the second quarter. American Century Companies Inc. now owns 69,285 shares of the company's stock valued at $200,000 after acquiring an additional 5,001 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Larimar Therapeutics by 26.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,008 shares of the company's stock valued at $111,000 after acquiring an additional 6,038 shares in the last quarter. Barclays PLC increased its position in shares of Larimar Therapeutics by 10.7% during the fourth quarter. Barclays PLC now owns 78,470 shares of the company's stock valued at $299,000 after acquiring an additional 7,577 shares during the last quarter. Finally, Rhumbline Advisers increased its position in shares of Larimar Therapeutics by 15.7% during the first quarter. Rhumbline Advisers now owns 65,018 shares of the company's stock valued at $140,000 after acquiring an additional 8,818 shares during the last quarter. 91.92% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近增加或減少了對該公司的持股。法國巴黎銀行金融市場在第三季度將其在 Larimar Therapeutics 的持股增加了 75.8%。法國巴黎銀行金融市場現在擁有 10,146 股該公司的股票，價值$33,000，在上個季度又購買了 4,376 股。美國世紀公司在第二季度將其在 Larimar Therapeutics 的持股增加了 7.8%。美國世紀公司現在擁有 69,285 股該公司的股票，價值$200,000，在上個季度又收購了 5,001 股。Price T Rowe Associates Inc. MD 在第四季度將其在 Larimar Therapeutics 的持股增加了 26.3%。Price T Rowe Associates Inc. MD 現在擁有 29,008 股該公司的股票，價值$111,000，在上個季度又收購了 6,038 股。巴克萊銀行在第四季度將其在 Larimar Therapeutics 的持股增加了 10.7%。巴克萊銀行現在擁有 78,470 股該公司的股票，價值$299,000，在上個季度又收購了 7,577 股。最後，Rhumbline Advisers 在第一季度將其在 Larimar Therapeutics 的持股增加了 15.7%。Rhumbline Advisers 現在擁有 65,018 股該公司的股票，價值$140,000，在上個季度又收購了 8,818 股。91.92% 的股票由機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>LRMR has been the topic of a number of analyst reports. Wedbush upped their target price on shares of Larimar Therapeutics from $12.00 to $13.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday. Citigroup lifted their price target on Larimar Therapeutics from $12.00 to $14.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, February 25th. Leerink Partners raised Larimar Therapeutics to a &#34;strong-buy&#34; rating in a report on Monday, January 5th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Finally, Lifesci Capital upgraded Larimar Therapeutics to a &#34;strong-buy&#34; rating in a report on Tuesday, February 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $16.43.</p>
<div class="lb-trans"><p>LRMR 成為多份分析師報告的主題。Wedbush 在週五的報告中將 Larimar Therapeutics 的目標價格從$12.00 上調至$13.00，並給予該股票 “跑贏大盤” 的評級。花旗集團在 2 月 25 日星期三的研究報告中將 Larimar Therapeutics 的目標價格從$12.00 上調至$14.00，並給予該公司 “買入” 評級。Leerink Partners 在 1 月 5 日星期一的報告中將 Larimar Therapeutics 的評級提升至 “強烈買入”。Weiss Ratings 在 1 月 22 日星期四的研究報告中重新發布了對 Larimar Therapeutics 的 “賣出（d-）” 評級。最後，Lifesci Capital 在 2 月 24 日星期二的報告中將 Larimar Therapeutics 的評級提升至 “強烈買入”。兩位股票研究分析師對該股票給予了 “強烈買入” 評級，七位給予了 “買入” 評級，一位給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “買入”，共識目標價格為$16.43。</p>
</div><p><strong>Read Our Latest Stock Report on LRMR</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 LRMR 的最新股票報告</strong></p>
</div><h2>About Larimar Therapeutics</h2>
<div class="lb-trans"><h2>關於 Larimar Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.</p>
<div class="lb-trans"><p>Larimar Therapeutics, Inc 是一家臨牀階段的生物技術公司，專注於利用其新型細胞穿透肽技術平台開發罕見疾病的治療方案。其主要產品候選藥物 CTI-1601 目前正在進行針對弗里德里希共濟失調的第二階段 OLE 臨牀試驗，這是一種罕見的、進行性且致命的遺傳疾病。Larimar Therapeutics, Inc 總部位於賓夕法尼亞州巴拉金伍德。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Larimar Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票，勝過 Larimar Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFJNUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LRMR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Larimar Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Larimar Therapeutics 嗎？</h2>
</div><p>Before you consider Larimar Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Larimar Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Larimar Therapeutics 並不在名單上。</p>
</div><p>While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Larimar Therapeutics 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看五隻股票</p>
</div>

Larimar Therapeutics (LRMR) 預計將在週一公佈財報